Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD).

NCT01682083 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

870

Enrollment

INDUSTRY

Sponsor class

Conditions

Melanoma

Interventions

DRUG: Dabrafenib
DRUG: Trametinib
DRUG: Placebos

Sponsor

Novartis Pharmaceuticals